
Synchron
Listed on
$
01234567890.0123456789001234567890
729.17% VALUATION CHANGE
VALUATION TRAJECTORY
Venture Mandate
Synchron is a pioneer in the field of brain-computer interfaces (BCIs). Their flagship product, the Stentrode, is an endovascular BCI that can be implanted without open brain surgery. It is designed to help patients with severe paralysis control digital devices using their thoughts. This funding will support FDA trials and commercialization efforts.
Valuation
$995.0M
Min. Entry
$10,000
Deal Type
Primary
Region
Currency
USD
Funding History
| Round | Date | Amount | Valuation |
|---|---|---|---|
Series C | Dec 2022 | $75.0M | $0.3B |
Series B | Jun 2021 | $40.0M | $0.1B |
Current Offering | Live Now | - | $15.12 / Share |
Market Pulse
Node:
Risk Audit Disclosures
Significant medical and regulatory risks.
Competition from other BCI companies like Neuralink.
Long road to profitability and market adoption.